Clinical Trial Update: A Safety and Tolerability Study of BIVV020 in Adults With Cold Agglutinin Disease [Phase 1]

View source ↗

Summary

This clinical trial update reports the completion of a Phase 1 safety and tolerability study of BIVV020 in adults with cold agglutinin disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Haemolytic Anaemia
• Cold Agglutinin Disease

Drugs mentioned

• BIVV020

Snippet

Sponsor: Bioverativ, a Sanofi company | Conditions: Autoimmune Haemolytic Anaemia | Phase 1 | Status: COMPLETED